BOSTON, Nov. 7, 2024
"Antibody drugs are advanced medicines designed to target specific disease-causing agents, cancer cells. The technology behind these drugs is rapidly advancing, and their market is expanding globally as more countries and companies invest in developing and using them to treat various illnesses."
Advertisement
BOSTON, Nov. 7, 2024 /PRNewswire/ -- "According to the latest study from BCC Research, Antibody Drugs: Technologies and Global Markets is expected to grow from $242.6 billion in 2024 to $412.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.2% during the forecast period of 2024 to 2029."
Advertisement
This study provides a comprehensive look at the different types of antibody drugs, including human, humanized, chimeric, and murine for the treatment of various diseases.
The report includes market projections, regulatory information, and updates on new products and technologies. It also profiles the leading makers of antibody drugs, such as AbbVie and Amgen.
The report focuses on how monoclonal antibodies (mAbs) are increasingly used for treating chronic diseases and covers four main application areas: autoimmune diseases, solid tumors, lymphoma and leukemia, and other conditions like asthma and osteoporosis.
(Note: Polyclonal antibodies, diagnostic uses, research applications, or COVID-19 related products are outside of the report's scope.)
Interesting and surprising facts:
To further explore the market's dynamics and growth opportunities, click here.
Factors contributing to the market's growth include:
Request a Sample Copy of Antibody Drugs: Technologies and Global Markets
Report Synopsis
Report Metrics
Details
Base year considered
2023
Forecast period considered
2024-2029
Base year market size
$218.6 billion
Market size forecast
$412.1 billion
Growth rate
CAGR of 11.2% for the forecast period of 2024-2029
Segments covered
Antibody type, manufacturing process type, and application
Regions covered
North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Countries covered
U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, China, Japan, India, South Korea, and Australia
Market drivers
• Growing incidence of cancer and autoimmune diseases.
• Increasing product approvals.
• Rising collaborations and partnerships for antibody drug development.
Leading companies in the market include:
Other related reports include:
Antibody-Drug Conjugates: Technologies and Global Markets: Antibody-Drug Conjugates (ADCs) are a new way to fight disease, where a targeted antibody is attached to a powerful medicine, allowing for a precise attack on cancer cells or other diseased cells, while sparing healthy cells, offering a promising approach to treating complex diseases with fewer side effects.
Global Recombinant Proteins Market: This report covers the worldwide industry that produces and sells proteins created through genetic engineering, which are used to develop life-saving medicines, treatments, and diagnostics for various diseases.
Directly purchase a copy of the report with BCC Research.
For further information on any of these reports or to purchase one, please get in touch with [email protected].
About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions, free of noise and hype.
Contact UsCorporate HQ: 50 Milk St. Ste 16, Boston, MA 02109, USA
Email: [email protected],
Phone: +1 781-489-7301
For media inquiries, email [email protected] or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
Logo - https://mma.prnewswire.com/media/2183242/5013934/BCC_Research_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/a-new-era-in-medicine-how-antibody-drugs-are-revolutionizing-healthcare-302299248.html
SOURCE BCC Research LLC
